Weight gain due to hormonal contraception: Myth or truth?;Gewichtsveränderung unter hormonalen Kontrazeptiva: Mythos oder wahrheit?

Gynakologisch-geburtshilfliche Rundschau

Volumn 49, Issue 2, 2009, Pages 87-93

  Häni, Daniela ^a,b   Imthurn, Bruno ^a   Merki Feld, Gabriele S ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Kantonsspital Baden   (Switzerland)

Author keywords

Ethinyl stradiol; Gestagene; Gewichtszunahme; Kontrazeption; Verh tungsmethoden

Indexed keywords

CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE;

CONTRACEPTION; DRUG SAFETY; DRUG USE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; REVIEW; SIDE EFFECT; WEIGHT FLUCTUATION; WEIGHT GAIN;

CONTRACEPTIVES, ORAL, HORMONAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; OBESITY; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; WEIGHT GAIN;

EID: 65249173535     PISSN: 10188843     EISSN: None     Source Type: Journal    
DOI: 10.1159/000197907     Document Type: Review

References (21)

1. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM: Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2006; 1:CD003987.
2. Flegal KM, Troiano RP: Changes in the distribution of body mass index of adults and children in the US population. Int J Obesity 2000; 24: 807-818.
3. Gulliford MC, Rona RJ, Chinn S: Trends in body mass index in young adults in England and Scotland from 1973 to 1988. J Epidem Commun Health 1992; 46: 187-190.
4. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW: A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra ® ). Fertil Steril 2002; 77: 19-26.
5. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW: Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98: 799-805.
6. Baker E, Ahrendt HJ: A one-year randomized trial comparing body weight and user acceptability with Nuva Ring ® and Yasmin ® . Obstet Gynecol 2005; 105(suppl):53S.
7. Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger I, Schellschmidt I, Heithecker R: Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25-34.
8. Oddsson K, Leifels-Fischer B, de Melo NR, Wiel-Masson D, Benedetto C, Verhoeven C, Dieben T: Efficacy and safety of a contraceptive vaginal ring (Nuva Ring ® ) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2004; 71: 176-182.
9. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R: A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptivescontaining either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124-134.
10. Risser WL, Gefter LR, Barrat MS, Risser JM: Weight change in adolescents who used hormonal contraception. J Adolesc Health 1999; 24: 433-436.
11. Endrikat J, Gerlinger C, Cronin M, Wessel J, Ruebig A, Rosenbaum P, Düsterberg B: Body weight change during use of a monophasic oral contraceptive containing 20 μ g ethinylestradiol and 75 μ g gestodene with a comparison of the women who completed versus those who prematurely discontinued intake. Eur J Contracept Reprod Health Care 2001; 6: 199-204.
12. Endrikat J, Düsterberg B, Ruegib A, Gerlinger C, Strowitzki T: Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999; 60: 269-274.
13. Barbosa IC, Filho CI, Faggion D, Baracat EC: Prospective open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 μ g and ethinylestradiol 15 μ g (Minesse ® ). Contraception 2006; 73: 30-33.
14. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J: Efficacy and safety of a lowdose 24-day combined oral contraceptive containing 20 μ g ethinylestradiol and 3 mg drospirenone. Contraception 2004; 70: 191-198.
15. Korver T, Dieben T, Vree M, van Muijen EA, Vromans L, van der Sanden A, van Osta G: A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μ g/day or levonorgestrel 30 μ g/day. Eur J Contracept Reprod Health Care 1998; 3: 169-178.
16. Clark MK, Dillon JS, Sowers M, Nichols S: Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obesity 2005; 29: 1252-1258.
17. Urbancsek J: An integrated analysis of nonmenstural adverse events with Implanon ® . Contraception 1998; 58: 109S-115S.
18. Funk S, Miller MM, Mishell DR, Archer DF, Poindexter A, Schmidt J, Zampaglione E: Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319-326.
19. Nilsson CG, Luukainen T, Diaz J, Allonen H: Clinical performance of a new levonorgestrel- releasing intrauterine device: a randomized comparison with a Nova-T-Copper device ® . Contraception 1982; 25: 345-356.
20. Hassan DF, Petta CA, Aldrighi JM, Bahamondes L, Perrotti M: Weight variation in a cohort of women using copper IUD for contraception. Contraception 2003; 68: 27-30.
21. Rekers H: Multicenter trial of monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand 1988; 67: 171-174.